Abbott Alere Merger Agreement

Alere believes that in diagnosing and monitoring health conditions, knowledge is now important™. Alere provides reliable and achievable information by providing rapid diagnostic testing and improving clinical and economic health care outcomes worldwide. Headquartered in Waltham, Mass., Alere focuses on rapid diagnosis of cardio-cellular diseases, infectious diseases and toxicology. For more information about Alere, please visit www.alere.com. In September 2016, Abbott Laboratories and Alere agreed to resolve their problems and reach mutual agreement on the agreement. In October, Alere shareholders accepted the agreement. What is remarkable is that the St. Jude medical agreement was approved five days later. In November 2016, Abbott Laboratories filed a complaint against Alere seeking the necessary information regarding the merger and asserting the breach of contract. Visit Abbott in www.abbott.com and contact us on Twitter at @AbbottNews. In Larkin v. Shah released last week, the Delaware Court of Chancery issued a shareholder challenge to a merger because of the cleanup effect of fully informed shareholders approval, the delaware Supreme Court`s most recent application…

In October, Abbott CEO Miles White said he still sees Alere as a « strategic adjustment » that would provide a « long-term post-sea opportunity. » The proposed transaction was stimulated at a time when European regulators approved the agreement until the sale of the reagent operations of Alere Epoc, Triage and BNP. This statement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. A number of important factors could lead to the actual results of Alere and its subsidiaries differing materially from those indicated in such forward-looking statements, including the risk that the proposed merger with Abbott could not be concluded, the absence of the necessary shareholder authorization, or the administrative authorization of the proposed merger; The risk factors in Part I, Item 1A, « Risk Factors » in our Management Report on Form 10-K for the year ended December 31, 2015 (as submitted to the SEC on August 8, 2016) and other risk factors identified from time to time in our periodic notifications to the SEC are present. These forward-looking statements are based on information, plans and estimates at the time of disclosure.